✓ BPD/Women’s Health – strong revenue growth following relaunch...

✓ BPD/Women’s Health – strong revenue growth following relaunch of NEXTSTELLIS® and from 2HFY23 launch of
women’s health portfolio products. Significant improvement in segment gross profit and direct contribution in
2HFY23 (positive on underlying basis)
✓ PPD/Dermatology – delivered significant 2HFY23 turnaround in revenue and gross margin following poor 1HFY23
performance with new commercial discipline to rebase business targeting sustainable and profitable growth
✓ International – revenue, gross profit and direct contribution growth delivered in 2HFY23 through CDMO activity.
Commenced business improvement program to improve plant efficiency and secure international CDMO growth